1. A Paradigm Shift in PAH

2. Program Goals

3. 2015 ESC/ERS Guidelines for PAH

4. 2015 ESC/ERS Risk Evaluation

5. Case Study Initial Evaluation

6. Invasive and Noninvasive Metrics

7. Shortcomings of 6MWD

8. Assessment of Risk

9. Monotherapy or Initial Combination Therapy?

10. An Evolving Paradigm From Sequential to Initial Upfront Combination Therapy

11. Achievement of Low-Risk Criteria

12. French Registry: Baseline Characteristics

13. Low-Risk Criteria

14. Low-Risk Criteria Achieved → 3-Year Survival

15. COMPERA Registry: Risk Stratification

16. COMPERA Registry: PAH Risk Assessment

17. Comprehensive Risk Stratification at Early Follow-Up Determines Prognosis

18. Clinical Follow-Up

19. Recommendations for Treatment Escalation in Patient on Background ERA + PDE5i

20. French Registry: Predictive Value of Individual Variables

21. French Registry: Predictive Value of Individual Variables (cont)

22. 3-Month Follow-Up After Therapy Initiated

23. Number of Low-Risk Criteria

24. Conclusion

25. Abbreviations

26. Abbreviations (cont)